https://pro.boehringer-ingelheim.com/my/ 2024-12-13T05:15:36+00:00 daily 1.0 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-focus-autoimmune-ilds 2026-02-17T10:24:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-diagnosis-treatment-atsersjrsalat-guideline 2024-12-16T06:47:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/importance-prompt-treatment-ipf 2026-02-02T13:35:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prescribing-information 2024-12-16T06:50:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology 2024-12-16T10:24:17+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular 2024-12-16T10:26:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic 2024-12-16T10:27:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation 2024-12-26T08:18:49+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/totality-outcome-of-afatinib-giotrif-sequential-treatment-in-patients-with-egfrm-nsclc 2024-12-16T06:51:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-drmaringer 2024-12-16T06:52:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-dramhoffmann-vold 2024-12-16T07:16:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/meet-expert-ask-me-anything-rheumatologists-series-2021-key-highlights-summary-droliver-distler 2024-12-16T07:17:26+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/telmisartan/video/delta-lock-structure 2024-12-16T07:18:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/telmisartan/video/cv-protection-benefits 2024-12-16T07:18:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/terms-use 2024-12-13T07:45:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/contact 2026-01-21T06:52:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate/prescribing-information 2024-12-16T07:19:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/telmisartan/video/what-edge-telmisartan-over-other-arbs-terms-anti-inflammatory-effects-diabetic-patients 2024-12-16T07:19:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prescribing-information/jardiance-prescribing-information 2024-12-16T07:21:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prescribing-information/jardiance-duo-prescribing-information 2024-12-16T07:22:12+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-pradaxa 2026-02-03T08:11:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate/prescribing-information/prescribing-information-praxbind 2026-02-03T08:11:24+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate 2024-12-16T09:05:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/resources 2026-02-13T13:20:48+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib 2025-02-18T04:32:58+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/efficacy 2023-09-05T08:25:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis 2023-09-12T13:18:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/telmisartan/video 2024-02-06T07:59:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/telmisartan 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing 2024-04-25T11:31:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view 2024-02-06T08:07:54+00:00 0.5 https://pro.boehringer-ingelheim.com/my/all-products 2024-12-13T08:42:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/privacy 2026-03-09T17:01:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/resources/metabolic 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/resources/cardiovascular 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/resources/oncology 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/resources/inflamation 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/videos 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/clinical-studies 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/test/video 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/prevent-the-stroke 2026-02-09T12:29:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ensure-safety 2026-02-13T10:48:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/reversibility-matters 2026-02-13T10:48:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/grace-campaign-teaser-video 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/graceful-with-prof-tang-renel-benifit 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/graceful-with-Prof-tang-glucose-lowering 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/graceful-with-prof-tang-adherence 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/prime-summit 2024-12-16T10:50:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment 2024-12-16T06:34:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/how-soon-can-we-initiate-sglt2i-treatment-in-your-hf-patients 2024-12-16T07:40:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-do-you-think-of-the-latest-esc-guidelines-on-treatment-for-hf 2024-12-16T07:39:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/2024-perak-medical-updates 2024-12-16T07:38:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-do-you-look-forward-most-latest-indication-jardiance 2024-12-16T07:37:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-biggest-unmet-need-hf-treatment 2024-12-16T07:37:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/how-do-you-recognise-hf-patient 2024-12-16T07:37:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/kidney-toolkit/risk-condition-and-evaluation 2024-12-16T10:46:40+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-value-jardiance-hf-treatment 2024-12-16T07:45:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/hfgt-what-value-jardiance-hf-treatment 2024-12-16T09:18:55+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/are-benefits-jardiance-similar-both-hfref-and-hfpef-treatment 2024-12-16T07:45:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/how-does-jardiance-simplify-hf-treatment 2024-12-16T07:45:03+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-benefits-would-jardiance-provide-your-patients 2024-12-16T07:44:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/heart-failure-got-treatment/what-doctors-experience-jardiance-safety-profile 2024-12-16T07:43:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/kidney-toolkit/treating-and-managing-ckd 2024-12-16T10:40:55+00:00 0.5 https://pro.boehringer-ingelheim.com/my/kidney-toolkit/risk-calculator 2024-12-16T10:42:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand 2024-12-16T05:16:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/afatinib/efficacy/giotrif-in-uncommon-mutation-a-database-analysis-of-1000-nsclc-patients 2024-12-16T05:15:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/ra-ild-risk-calculator-home 2025-02-13T11:10:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/ra-ild-screening-algorithm 2024-12-16T05:11:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/pradaxa/dose-calculator/dvtpe 2024-12-24T12:15:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/pradaxa/dose-calculator/thr-tkr 2024-12-24T12:16:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/pradaxa/dose-calculator/spaf 2024-12-24T12:13:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/ra-ild-risk-calculator 2024-12-16T07:48:12+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/in-your-practice-what-common-patient-risk-factors-you-see-that-increases-index-suspicion-ckd-and-how-do-go-about-making-the-diagnosis 2024-12-16T05:02:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empa-kidney-stepping-next-level-chronic-kidney-disease-management 2024-12-16T10:45:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/kidney-toolkit 2024-02-19T06:48:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/patient-stories/pradaxa-patient-and-ee-video-with-focus-on-ensure-safety-for-the-digital-multichannel-campaign 2026-02-13T10:47:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/when-life-happens/pradaxa-video-with-focus-on-reversibility-matters-for-the-digital-multichannel-campaign 2026-02-13T10:46:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/patient-stories/pradaxa-patient-and-ee-video-with-focus-on-prevent-the-stroke-for-the-digital-multichannel-campaign 2026-02-13T10:47:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/efficacy/inbuild-trial-efficacy-ra-ild-subgroup-analysis-dr-volkmann 2024-12-16T07:49:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/importance-mdd-managing-ctd-ild-patients-dr-volkmann 2024-12-16T07:49:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/risk-factors-progressive-ra-ild-dr-volkmann 2024-12-16T07:51:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/ild-ssc-when-consider-treatment-dr-volkmann 2024-12-16T07:52:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/time-essence-suspect-fibrotic-interstitial-lung-disease 2024-12-16T07:52:48+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-pulmonary-fibrosis-hrct-scans-rheum 2024-12-16T07:53:20+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/how-can-we-improve-shared-care-approaches-for-specialist-and-primary-care-physicians-in-managing-patients-with-ckd-and-cardio-renal-and-metabolic-conditions-for-better-patient-care 2024-12-16T04:48:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/when-there-newly-diagnosed-ckd-patient-with-hypertension-which-class-of-drug-would-you-consider-as-first-line-treatment 2024-12-16T04:46:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/in-diabetic-patient-newly-diagnosed-with-ckd-not-on-sglt2i-how-is-your-practice-initiating-sglt2i-if-patient-is-also-not-on-raasi 2024-12-16T04:45:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/hypertensive-newly-diagnosed-with-ckd-not-on-sglt2i-what-is-your-usual-approach-managing-this-patient-based-on-your-practice 2024-12-16T04:44:26+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/how-should-we-look-at-the-egfr-slope-decline-of-empagliflozin-in-empa-kidney-based-on-albuminuric-subgroups-a1-a2-a3 2024-12-16T04:43:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/should-we-consider-using-sglt2i-among-a1-a2-patients-with-ckd-empa-kidney-how-should-we-look-at-the-egfr-slope-decline-of-empagliflozin-in-empa-kidney-based-on-albuminuric-subgroups-a1-a2-a3 2024-12-16T04:42:10+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-your-thoughts-around-why-there-was-late-separation-between-empagliflozin-and-placebo-in-the-kaplan-meier-curve-for-the-primary-endpoint-in-empakidney 2024-12-16T04:41:12+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/in-your-practice-once-patient-diagnosed-with-ckd-how-do-you-initiate-sglt2i 2024-12-16T04:40:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/how-you-see-primary-care-physicians-laying-role-in-early-diagnosis-and-prompt-treatment-of-ckd 2024-12-16T04:39:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-your-thoughts-on-cardio-renal-and-metabolic-benefits-of-use-of-SGLT2i-and-its-use-your-patient-with-dm-hf-and-ckd 2024-12-16T04:36:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-you-are-important-renal-outcomes-to-remember-empa-reg-and-empa-kidney-that-demonstrates-benefit-of-sglt2i-in-ckd 2024-12-16T04:35:37+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/cv-mortality-and-hhf-and-cv-death-secondary-endpoint-not-reach-statistical-significance-in-empa-kidney 2024-12-16T04:34:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/how-would-you-explain-mechanistically-how-sglt2i-works-as-treatment-for-ckd 2024-12-16T04:33:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/patient-stories 2026-02-09T12:34:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/when-life-happens 2026-02-09T12:35:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-impact-in-the-composite-of-kidney-disease-progression-and-cv-death-in-ckd-patients-based-on-albuminuric-status-a1-a2-and-a3 2024-12-16T04:27:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-important-risk-factors-considered-for-the-development-of-ckd-based-on-epidemiology-and-your-practice 2024-12-16T04:26:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-benefit-in-all-cause-hospitalization-of-empagliflozin-in-the-a1-and-a2-subpopulation 2024-12-16T04:25:17+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-was-the-benefit-observed-of-the-use-of-empagliflozin-in-t2d-patients-with-ckd-based-on-ero-and-now-empakidney 2024-12-16T04:24:12+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/when-is-the-best-time-to-initiate-sglt2i-in-ckd-patients 2024-12-16T04:23:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-current-limitation-of-raas-inhibitor-and-what-is-the-additional-benefit-of-using-sglt-2-inhibitors-in-ckd 2024-12-16T04:22:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-benefit-observed-among-asian-patients-included-in-empakidney-based-on-the-Primary-outcome-of-composite-of-kidney-disease-progression-and-cv-death 2024-12-16T04:21:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/to-which-patients-should-we-give-empagliflozin-for-which-patient-co-morbidities-should-we-consider-early-initiation-of-sglt2i-to-optimize-organ-protective-benefits 2024-12-16T04:19:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-role-of-early-diagnosis-and-treatment-prompt-initiation-of-therapy-including-sglt-2-inhibitors-in-ckd-Progression 2024-12-16T04:18:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/there-seems-to-be-equivocal-or-no-benefit-in-kidney-disease-progression-in-patients-with-a1-and-a2-albuminuria-subgroups-in-empakidney-whats-your-point-of-view-in-these-results 2024-12-16T04:17:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-role-of-physicians-in-the-early-diagnosis-and-prompt-treatment-and-nephrology-referral-of-ckd-patients 2024-12-16T04:16:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-the-significance-of-the-primary-endpoint-of-kidney-disease-progression-and-cv-death-regardless-of-diabetes-status-as-an-outcome-and-what-does-this-mean-for-physicians-and-ckd-patients 2024-12-13T13:58:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-is-unique-of-empa-kidney-study-design-anD-difference-in-previously-available-ckd-trials-published-how-would-you-characterize-ckd-patien-population-empakidney-in-relation-previous-ckd-trials 2024-12-16T09:16:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-the-multiple-benefits-you-see-in-the-use-of-empagliflozin-in-a-patient-with-t2d-hf-and-ckd 2024-12-13T13:56:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-your-thoughts-on-the-primary-outcome-of-the-composite-of-kidney-disease-progression-results-on-empa-kidney-trial-and-implications-in-practice 2024-12-13T13:55:17+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/should-sglt2i-be-discontinued-if-egfr-levels-fall-below-20ml-min 2024-12-13T13:52:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/should-there-be-a-safety-concern-for-the-egf-dip-in-initiating-sglt2i-in-ckd-patients 2024-12-13T15:22:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/how-do-we-translate-the-benefit-in-egfr-slope-decline-of-empagliflozin-based-on-empower-trials-from-ero-emperor-studies-and-empa-kidney-in-clinical-practice 2024-12-16T09:16:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/is-there-benefit-in-egfr-slope-decline-of-empagliflozin-based-on-empower-trials-from-ero-emporor-studies-and-empa-kidney 2024-12-16T09:16:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-your-thoughts-on-the-results-of-the-primary-outcome-of-the-composite-of-kidney-disease-progression-and-cardiovascular-death-of-empagliflozin-based-on-the-empa-kidney-trial 2024-12-16T09:15:40+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/meet-the-expert-series-video-on-demand/what-are-the-current-guidelines-recommendation-on-the-use-of-sglt-2-inhibitors-in-t2d-and-ckd 2024-12-16T09:15:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/seems-seems-like 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series 2024-12-16T08:25:17+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/how-do-provide-holistic-care-patient-risk-crm-diseases 2024-12-16T08:26:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/when-do-refer-patient-risk-end-stage-renal-disease 2024-12-16T08:31:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/what-current-upcoming-ckd-guidelines 2024-12-16T08:31:10+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/how-can-sglt2i-help-patients-iga-nephropathy 2024-12-16T08:32:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/what-benefits-empagliflozin-on-ckd-empa-kidney 2024-12-16T08:32:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/not-all-dpp4i-are-the-same-safety-profile 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/what-common-signs-symptoms-patient-with-ckd 2024-12-16T08:32:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/not-all-dpp4i-are-the-same-dosing 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/how-can-spot-potential-ckd-patient 2024-12-16T08:32:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/not-all-dpp4i-are-the-same-simplicity 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-merlin-thomas-ckd-video-series/what-lifestyle-practices-lead-ckd 2024-12-16T08:33:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney 2024-12-23T13:16:37+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-what-are-the-major-challenges-today-with-treating-kidney-disease 2024-12-16T08:40:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-do-the-empa-kidney-results-add-up-to-the-existing-strong-scientific-evidence-of-empagliflozin 2024-12-16T08:41:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-important-is-early-diagnosis-and-intervention-when-it-comes-to-ckd 2024-12-16T08:42:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-do-the-outcomes-of-the-empa-kidney-trial-help-patients-suffering-from-kidney-disease 2024-12-16T09:08:34+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-does-this-early-intervention-impact-the-heart 2024-12-16T09:09:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-for-you-as-a-nephrologist-in-your-daily-practice-what-is-the-most-impactful-outcome-that-was-shown-in-the-empa-kidney-trial 2024-12-16T09:10:10+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-do-you-interpret-the-results-of-the-primary-outcome-of-empa-kidney 2024-12-16T09:11:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-do-you-interpret-the-importance-of-empa-kidney-results-with-regards-to-the-treatment-of-patients-with-ckd 2024-12-16T09:10:49+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-how-relevant-is-the-broad-patient-population-within-empa-kidney-for-a-general-practitioners-daily-practice 2024-12-16T08:24:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/prof-christoph-wanners-take-on-empa-kidney/prof-christoph-wanner-what-is-a-typical-patient-that-may-benefit-from-the-empa-kidney-trial-results 2024-12-16T08:23:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/immunology/spevigo/gpp-reels-1-use-of-IV-spesolimab-in-gpp-patient-with-underlying-plaque-psoriasis 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empowering-physicians-in-kidney-disease-management 2024-12-16T11:13:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/specialty/ofev/4th-regional-ild-masterclass-agenda 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-lift-option-summary-1 2025-01-29T10:44:20+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-lift-option-summary-2 2025-01-29T10:45:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-stairs-option-summary-1 2025-01-29T10:45:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-stairs-option-summary-2 2025-01-29T10:45:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-option-summary-1 2025-01-29T10:46:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-option-summary-2 2025-01-29T10:47:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-taxi-summary-1 2025-01-29T10:47:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-walking-summary-1 2025-01-29T10:47:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-taxi-summary-2 2025-01-29T10:48:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-walking-summary-2 2025-01-29T10:48:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-bicycle-summary-1 2025-01-29T10:49:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/seems-bus-bicycle-summary-2 2025-01-29T10:49:49+00:00 0.5 https://pro.boehringer-ingelheim.com/my/sample-test-page 2026-02-11T11:00:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/ae-management-focus-diarrhoea 2024-12-16T08:21:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety 2024-12-16T08:19:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/ae-management-focus-paronychia 2024-12-16T08:21:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/scalp-lesion-management 2024-12-16T08:20:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/ae-management-focus-skin-rash 2024-12-16T08:17:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/stomatitis-management 2024-12-16T08:16:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/safety/xerosis-management 2024-12-16T08:15:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive 2024-12-16T08:13:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/uptake-subsequent-therapy-lux-lung-3-6-and-7 2024-12-16T08:12:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/dosing-and-administration 2024-12-16T08:10:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/dosing-and-administration/results-realgido-global-real-world-study 2024-12-16T08:19:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/post-hoc-analyses-lux-lung-trials-giotrifr-followed-3rd-generation-tki 2024-12-16T07:58:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib 2024-12-16T07:58:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki 2024-12-16T07:59:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-south-korea-reset-study 2024-12-16T07:59:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-upswing-sequential-cohort 2024-12-16T07:59:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/dosing-and-administration/management-giotrif-adverse-events-real-world 2024-12-16T07:59:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/totality-outcome-afatinib-giotrif-sequential-treatment-patients-egfrm-nsclc 2024-12-16T08:00:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite-dose-modification 2024-12-16T08:00:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif 2024-12-16T08:00:45+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-gioswing-sequential-cohort-combined-analysis 2024-12-16T08:01:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/rwdri-real-world-effectiveness-sequential-giotrif-osimertinib-data-giotag-and-reset-studies 2024-12-16T08:01:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/sequencing/sequential-treatment-afatinib 2026-02-17T12:00:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly 2024-12-16T08:02:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-significantly-reduces-relative-risk-disease-progression-or-death-vs-gefitinib 2024-12-16T08:02:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/consistent-efficacy-giotri-observed-across-real-world-studies 2024-12-16T08:02:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations 2024-12-16T08:03:07+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-qa 2025-01-29T11:04:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/taiwan-real-world-data 2024-12-16T08:03:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-delays-median-time-cns-progression-versus-chemotherapy 2024-12-16T08:07:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-real-world-data-patientss-cns-involvement 2024-12-16T08:07:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-lecture 2025-01-29T11:04:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/uncovering-uncommon-efficacy-afatinib-uncommon-and-compound-mutations 2025-01-29T11:05:24+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-brain-metastases-data-korea-and-taiwan 2024-12-16T08:08:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-vs-osimertinib-data-japan 2024-12-16T08:07:07+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/personalized-approach-lung-adenocarcinoma-egfr-tki-therapy-prolong 2025-01-29T11:06:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/running-marathon-updated-evidence-sequential-egfr-tki-approach-nsclc 2025-01-29T11:07:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/eee-online-modules/running-marathon-updated-evidence-sequential-egfr-tki-approach-nsclc-qa-session 2025-01-29T11:07:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/treatment-stratergy-EGFR 2025-01-29T11:07:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/strategies-managing-egfrm-nsclc 2025-01-29T11:10:12+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/videos/prof-per-hendrik-groop-videos/prof-groop-3 2025-03-07T06:24:54+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc 2024-12-16T07:38:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/effectiveness-dose-modification-strategies-afatinib 2025-01-29T11:10:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/evidence-sequential-therapy-egfr-m-nsclc 2025-01-29T11:09:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/egfr-tki-related-dermatological-adverse-events 2025-01-29T11:09:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-treatment-nsclc-harbouring-uncommon-egfr-mutations-published-pooled-analysis-693 2024-12-16T07:43:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-south-korea 2024-12-16T07:42:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/video-uncommon-egfr-pooled-analysis-693-patients 2024-12-26T06:53:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/expert-conversations/tumour-heterogenity 2025-01-29T11:09:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/videos 2025-03-07T06:07:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk 2024-12-16T07:41:45+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/guidelines-recommend-4-pillar-approach-managing-hfref-what-practical-approach 2024-12-16T07:41:29+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/how-has-hfpef-guidelines-evolved-advent-sglt2i-trials 2024-12-16T07:41:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/what-impact-treatment-landscape-early-benefits-seen-emperor-trials 2024-12-16T07:40:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/what-do-we-know-about-consistency-results-empagliflozin-across-spectrum-ejection 2024-12-16T07:40:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/what-role-empagliflozin-patients-hospitalized-heart-failure 2024-12-16T07:40:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-taiwan 2024-12-16T07:40:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/lets-talk/what-makes-sglt2i-ideal-hf-therapy 2024-12-16T07:40:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-evidence-giotrif-japan 2024-12-16T07:39:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-safety-and-effectiveness-real-world 2024-12-16T07:39:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/first-line-giotrif-data-over-30-real-world-studies-date 2024-12-26T06:29:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/south-korean-dataset-frontline-giotrif-uncommon-egfr-mutations 2024-12-16T07:34:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response 2024-12-16T07:33:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate/publications 2024-12-16T07:34:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme 2024-12-26T07:51:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory 2024-12-20T13:12:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/tovito 2024-04-21T18:34:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto 2024-04-22T04:11:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/empact-mi-results-journal-paper 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/actilyse-my-pi 2026-01-12T10:16:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/giotrif-my-pi 2026-01-12T10:16:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/spiolto-respimat-my-pi 2024-12-26T06:55:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/spiriva-respimat-my-pi 2025-03-18T07:25:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/twynsta-my-pi 2024-12-26T05:02:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/micardis-plus-my-pi 2024-12-26T05:03:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/graceful-with-prof-tang-cardiovascular-benefit 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/micardis-my-pi 2024-12-26T04:52:09+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/metalyse-my-pi 2026-01-12T10:25:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/pradaxa-my-pi 2026-01-12T10:17:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/glyxambi-my-pi 2026-01-12T10:17:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/jardiance-my-pi 2026-01-12T10:18:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/jardianceduo-my-pi 2026-01-12T10:18:26+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/praxbind-my-pi 2026-01-12T10:19:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/trajenta-my-pi 2026-01-12T10:19:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/trajentaduo-my-pi 2024-12-26T07:36:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/graceful-with-prof-tang-safety-profile 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/mobic-my-pi 2026-01-12T10:15:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/ofev-my-pi 2026-01-12T10:15:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/sifrol-my-pi 2026-01-12T10:13:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/sifrol-er-my-pi 2026-01-12T10:12:53+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy 2024-12-16T07:31:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps 2024-12-20T06:44:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/seems-and-seems-like 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cvm-congress-2024/post-webinar-video 2024-12-24T14:55:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cvm-congress-2024/post-webinar-video-q-and-a 2024-12-24T15:10:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/kcs-post-webinar 2024-12-16T11:25:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/prime-summit-2024 2024-12-16T11:29:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance 2024-12-26T11:01:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/hcps-role-in-ckd-management-when-to-refer 2024-12-26T11:04:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/pcps-role-in-dkd-management-and-when-to-refer-to-endocrinologist 2024-12-26T11:04:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/what-does-kidney-function-preservation-in-empa-kidney-mean-to-you 2024-12-26T11:05:03+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empowering-pharmacists-mastering-cardiovascular-metabolic-care 2025-01-15T05:41:34+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/how-to-identify-progression-in-fibrotic-ild-radiology-expert-excerpt 2024-12-16T07:31:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/rationale-for-early-antifibrotic-treatment-in-pf-ild-video-snippet 2024-12-16T07:31:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/real-world-first-line-giotrif-for-egfrm-nsclc-updated-survival-data-from-korea 2024-12-26T06:32:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/why-even-wait-until-there-is-10-relative-fvc-decline-physician-perspective-video-snippet 2024-12-16T07:31:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/optimizing-treatment-of-patients-with-pf-ild-with-patient-case-study-expert-lecture 2024-12-16T07:24:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-tips-for-differentiating-hp-from-idiopathic-pulmonary-fibrosis 2024-12-16T07:24:20+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-what-are-the-treatment-options-for-patients-with-hp 2024-12-16T07:23:58+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-how-to-monitor-patients-with-hp-for-progression-and-identify-ppf-early 2024-12-16T07:23:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-how-to-treat-progressive-fibrotic-hp 2024-12-16T07:23:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-the-experts-practical-experience-with-ofev-nintedanib 2024-12-16T07:23:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-talk-the-future-of-treatment-for-hp 2024-12-16T07:21:45+00:00 0.5 https://pro.boehringer-ingelheim.com/my/immunology/spesolimab/gpp-reels-2-use-of-iv-spesolimab-in-gpp-patient-who-failed-oral-systemic-agents 2024-12-26T11:06:03+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/toolbelt-video-clinical-relationship-between-heart-and-kidneys-angermann-and-carvalho-1 2025-01-17T14:19:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/why-is-empa-now-a-preferred-hf-treatment-angermann-and-carvalho 2025-01-17T14:12:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/how-has-recent-evidence-changed-the-management-of-hf-angermann-and-carvalho 2025-01-17T14:09:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties 2024-12-16T07:20:10+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/prof-mcdonagh-esc-2023-guidelines 2025-01-17T13:57:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/carmelina-cvot-renal-outcome-significance-explained 2026-02-18T10:11:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/which-type-of-patients-can-dpp4i-monotherapy-be-more-beneficial 2024-12-26T11:07:55+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/is-dpp4i-suitable-for-admitted-patients 2024-12-26T11:09:10+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/summary-its-simple-its-all-about-them 2024-12-26T11:09:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/patient-profiles-its-simple-its-all-about-them 2024-12-26T11:10:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/not-all-dpp4i-are-the-same-dosing-simplicity 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/which-is-the-simplest-dpp4i-in-your-clinical-practice 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/evidences-on-combination-of-trajenta-jardiance 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/updated-guidelines-on-dpp-4-inhibitors-for-type-2-diabetes 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/trajenta/type-2-diabetes-landscape-changes-with-dpp-4-inhibitors 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/why-is-empagliflozin-your-first-option-to-initiate-in-hf-subodh-verma 2025-01-17T14:05:26+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/endocrinology/professional-tips-on-t2d-patient-outcomes 2025-01-17T13:42:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/endocrinology/diabetic-ketoacidosis 2025-01-17T13:28:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/endocrinology/expert-opinions-regarding-uti-gti 2025-01-17T13:23:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/endocrinolgy/practical-tips-animation-video-elderly-frailty 2025-01-17T13:39:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/benefits-of-starting-an-sglt2i-upon-clinical-diagnosis-of-hf-subodh-verma 2025-01-17T14:03:24+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/crucial-patients-for-high-index-suspicion-of-hf-subodh-verma 2025-01-17T14:00:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/endocrinology/expert-opinions-regarding-egfr-dip 2025-01-17T13:25:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/is-the-initial-egfr-dip-a-concern-angermann-and-carvalho 2025-01-17T14:17:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/lets-talk-impact-of-sglt2i-trials-in-hfpef 2025-01-27T08:22:58+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts/cardiology/lets-talk-impact-of-early-benefits 2025-01-27T08:31:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/cardiology 2024-12-16T07:11:58+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/nephrology 2024-12-16T07:12:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/endocrinology 2024-12-16T07:11:48+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care 2024-12-16T07:09:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/shorts 2024-12-16T07:09:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/upcoming-events 2024-12-16T07:09:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/past-events 2024-12-16T07:09:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources 2024-12-16T07:08:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/patient-materials 2024-12-16T07:08:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/cardiology/shorts 2024-12-16T07:08:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/cardiology/upcoming-events 2024-12-16T07:07:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/cardiology/past-events 2024-12-16T07:07:09+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/cardiology/patient-materials 2024-12-16T07:06:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/nephrology/past-events 2024-12-16T07:06:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/endocrinology/shorts 2024-12-16T07:05:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/endocrinology/resources 2024-12-16T07:03:14+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/endocrinology/patient-materials 2024-12-16T06:55:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care/shorts 2024-12-16T06:55:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care/upcoming-events 2024-12-16T06:56:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care/past-events 2024-12-16T06:56:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care/resources 2024-12-16T06:56:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/primary-care/patient-materials 2024-12-16T06:56:57+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/endocrinolgy/4-steps-to-holistic-t2dm-management 2025-01-17T13:45:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/endocrinolgy/sick-days-rule-sadmans 2025-01-17T13:51:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/management-approach-for-people-with-t2d 2025-01-17T13:47:28+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/endocrinology/t2dm-guideline 2025-01-17T13:44:02+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/nephrology/medication-guideline-for-t2dm 2025-01-17T13:21:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/resources/endocrinolgy/2022-kdigo-guideline-summary 2025-01-17T14:23:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/patient-materials/endocrinology/what-does-sglt2i-do 2025-01-17T13:53:27+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/patient-materials/endocrinology/tips-for-enjoying-the-benefits-of-taking-the-sglt2i2-without-worries 2025-01-17T13:54:55+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cvm-congress-2024/2nd-event-post-webinar-video-lecture 2024-12-26T11:11:03+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cvm-congress-2024/2nd-event-post-webinar-video-qna 2024-12-26T11:11:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiometabolic/events/prime-summit-3-2024 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-wanner-3-early-kidney-screening-by-pcp 2024-12-26T11:16:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-green-1-key-summary-2022-easd-ada-2022-kdigo 2024-12-26T11:16:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/dr-brendon-26-6yrs-delay-of-kidney-replacement-therapy 2024-12-26T11:12:20+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-green-2-importance-of-egfr-and-uacr-screening 2024-12-26T11:12:37+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-jarvis-1-tips-for-sip-when-initiating-sglt2i-in-t2d 2024-12-26T11:12:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-wanner-1-ero-renal-data 2024-12-26T11:13:09+00:00 0.5 https://pro.boehringer-ingelheim.com/my/oncology/giotrif/efficacy/vietnam-rwd-2024 2024-12-16T06:49:03+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm 2024-12-16T06:49:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-on-screening-pcp 2024-12-16T06:49:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-on-how-is-egfr-slope-a-viable-surrogate-endpoint-for-kidney-disease-progression-in-clinical-trials 2024-12-16T06:49:54+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-on-starting-sglt2i-in-lower-egfr-egfr-dip-brendon-neuen 2024-12-16T06:50:20+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-on-role-of-screening-for-hcps-in-general-brendon-neuen 2024-12-16T06:50:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-on-benefits-of-starting-a1-and-a2-patients-regardless-of-raasi-use-at-baseline-with-empagliflozin 2024-12-16T06:50:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/experts-opinion-video-on-synergistic-relationship-between-raasi-and-sglt2i 2024-12-16T06:51:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/voice-of-crm/expert-opinion-on-raasi-dose-optimization-before-addition-of-sglt2i-brendon-neuen 2024-12-16T06:51:29+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/efficacy-and-safety-of-sglt2-i-with-and-without-glp-1-agonists 2024-12-24T13:18:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/kcs-post-webinar-9 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/latest-update-on-ctd-ild-management-by-dr-voon-ong 2024-12-16T06:51:34+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-care-insights-from-an-ild-nurse-specialist 2024-12-16T06:51:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/importance-of-early-referral-in-ctd-ild 2024-12-16T06:52:09+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/monitoring-patients-with-ctd-ild-best-practices 2024-12-16T06:52:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/nintedanibs-role-in-ctd-ild-management 2024-12-16T06:52:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/maintaining-treatment-adherence-in-ctd-ild 2024-12-16T06:53:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/when-to-start-treatment-for-ssc-ild 2024-12-16T06:47:19+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/nintedanib-in-ra-ild-insights-from-the-inbuild-trial 2024-12-16T06:47:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi/tprof-kaul-eov-ominous-octet-pathway 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/clinical-guidelines/type-2-diabetes 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/clinical-guidelines/heart-failure 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/clinical-guidelines/chronic-kidney-disease 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/expert-view/ild-masterclass-2024-post-event-newsletter 2024-12-16T06:48:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/glyxambi 2024-12-11T12:48:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/hf-webinar 2025-09-30T06:19:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/past-events/cardiology/prime-summit-2-day-1 2024-12-26T10:50:51+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/jardiance/all-specialties/past-events/cardiology/prime-summit-2-day-2 2024-12-26T10:52:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/spevigo-vial-my-pi 2024-12-24T13:01:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/immunology/gpp-reels-3-dr-latha 2024-12-26T11:13:59+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-esc-hfa-nt-probnp-thresholds-for-new-hf-diagnosis 2025-01-29T09:22:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-screening-for-cardiovascular-kidney-metabolic-syndrome 2025-01-29T09:23:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-how-do-i-diagnose-and-manage-hfpef 2025-01-29T09:23:54+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-cardiorenal-effects-of-empagliflozin-after-ami 2025-01-29T09:24:45+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-hfpef-scoring-and-interpretation 2025-01-29T09:25:11+00:00 0.5 https://pro.boehringer-ingelheim.com/my/ropu-comparative-sglt2i-rwe 2025-01-29T09:26:30+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar1-by-dr-goh-eng-leong 2026-02-17T12:23:44+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/if-you-were-choosing-a-car-which-one-would-you-prefer 2025-01-28T08:12:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/what-other-add-on-benefits-in-an-antihypertensive-that-you-would-want-for-your-patients 2025-01-28T07:54:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/significant-blood-pressure-reduction-sustained-over-24-hours1-2 2025-01-28T08:15:26+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/ontarget-filled-the-cv-high-risk-patient-gap-in-the-cv-continuum 2025-01-28T08:17:22+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/add-on-benefits-in-antihypertensive-patients 2025-02-04T04:10:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/2023-esh-hptn-guidelines-spcs-are-favoured-as-improves-treatment-adherence-and-increases-rate-of-bp-control 2025-01-28T08:16:23+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/hypertensive-care 2025-01-28T08:15:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/how-long-of-a-medication-half-life-would-you-prefer-for-your-patients 2025-01-28T07:52:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/what-would-you-seek-for-in-an-antihypertensive-medication 2025-01-28T07:53:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/which-would-be-a-preferred-antihypertensive-treatment-according-to-guidelines 2025-01-28T07:54:06+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/which-group-of-patients-would-you-consider-for-an-antihypertensive 2025-01-28T07:55:05+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/If-you-had-a-choose-how-long-would-you-prefer-a-fuel-tank-to-last-before-needing-a-refill 2025-01-28T08:11:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/if-you-were-repairing-a-leak-which-one-would-you-prefer 2025-01-28T08:12:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/when-installing-security-cameras-which-areas-would-you-prefer-to-cover 2025-02-04T04:16:34+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta/if-you-were-picking-insurance-for-your-car-what-would-you-want 2025-01-28T08:13:21+00:00 0.5 https://pro.boehringer-ingelheim.com/my/synchronize-cvot-survodutide-obesity-phase-3-cvd-ckd 2025-02-04T03:29:55+00:00 0.5 https://pro.boehringer-ingelheim.com/my/survodutide-a-dual-agonist-for-obesity-and-mash 2025-02-04T03:30:17+00:00 0.5 https://pro.boehringer-ingelheim.com/my/empagliflozin-and-early-dkd-biomarkers-eurobeat-study 2025-02-04T03:30:35+00:00 0.5 https://pro.boehringer-ingelheim.com/my/empagliflozin-and-glp-1-receptor-agonists-combo-in-t2d 2025-02-04T03:30:48+00:00 0.5 https://pro.boehringer-ingelheim.com/my/t2d-sglt2-inhibitors-on-cardiovascular-outcomes 2025-02-04T03:30:56+00:00 0.5 https://pro.boehringer-ingelheim.com/my/glycemic-control-and-preventing-cardiovascular-disease 2025-02-04T03:30:04+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/twynsta 2025-01-15T15:08:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/actilyse/actilyse-50mg-reconstitution-video 2025-02-10T06:07:13+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/metalyse/metalyse-50mg-reconstitution-video 2025-02-10T06:07:32+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar2-by-dr-lydia 2026-02-17T12:24:43+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/jardiance-10-years-hcp-testimonial-video-1 2026-02-18T10:10:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar1-by-dr-ng-eng-khim 2026-02-17T12:27:24+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar1-by-dr-gary-lee 2026-02-17T12:25:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar1-q-a 2026-02-17T12:30:42+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/enhance-crm-webinar2-chat-with-experts 2026-02-17T12:28:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/atrial-fibrillation-heart-failure 2026-02-18T10:08:39+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/case-study-on-sub-clinical-af 2026-02-18T10:09:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/atrial-fibrillation-obesity 2026-02-18T10:07:31+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/case-study-on-ckd-in-af 2026-02-18T10:06:46+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/case-study-on-cryptogenic-stroke 2026-02-18T10:06:01+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation/atrial-fibrillation-obstructive-sleep-apnea 2026-02-18T10:05:08+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/meet-john-ipf-patient-journey 2025-02-26T08:02:52+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/meet-daniel-ra-ild-patient-journey 2025-02-26T08:02:45+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/nintedanib/about-pulmonary-fibrosis/meet-kim-ssc-ild-patient-journey 2025-02-26T08:02:38+00:00 0.5 https://pro.boehringer-ingelheim.com/my/respiratory/spiolto/publications 2025-03-04T11:39:15+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empowering-pharmacists-mastering-cardio-renal-metabolic-care 2025-02-24T12:38:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/dabigatran-etexilate/dosing-calculator 2025-03-03T08:36:33+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/pradaxa/atrial-fibrillation 2025-03-03T07:35:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/videos/beneath-the-ice-animated-video 2025-04-04T11:57:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/international-guidelines/2023-sard-ild-guideline-poster 2025-05-14T03:54:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/international-guidelines/2023-ssc-recommendations 2025-04-08T10:14:16+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/international-guidelines/2023-sard-ild-guideline-leaflet 2025-05-14T03:55:50+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/international-guidelines/2023-ssc-recommendations-infographic 2025-05-14T03:55:29+00:00 0.5 https://pro.boehringer-ingelheim.com/my/inflammation/pf360/pulmonary-fibrosis 2025-05-16T07:09:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/actilyse/act-smart-q 2025-05-27T13:25:36+00:00 0.5 https://pro.boehringer-ingelheim.com/my/cardiovascular/actilyse 2025-05-06T10:15:40+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/empagliflozin/when-time-meets-power 2025-06-13T13:26:47+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/emphasis-highlights-2025 2026-02-17T12:28:41+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/empire-lite-highlights-2025 2026-02-17T12:29:00+00:00 0.5 https://pro.boehringer-ingelheim.com/my/metabolic/jardiance/national-act-smart-q-workshop-highlights-2025 2026-02-17T12:29:18+00:00 0.5 https://pro.boehringer-ingelheim.com/my/products/contact-us 2026-01-21T06:45:25+00:00 0.5 https://pro.boehringer-ingelheim.com/my/list-of-products-hcps/tenecteplase-metalyse-my-pi 2026-01-20T07:54:59+00:00 0.5